Ionis Pharmaceuticals IONS Debt conversion inducement expense
Debt conversion inducement expense at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InducedConversionOfConvertibleDebtExpense.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's debt conversion inducement expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's debt conversion inducement expense?
- Ionis Pharmaceuticals (IONS) reported debt conversion inducement expense of $4.09M in Q4 2025.
- What does debt conversion inducement expense mean?
- The cost of incentivizing debt holders to convert their debt into company stock early.
- How do you interpret debt conversion inducement expense?
- An increase suggests active debt restructuring or a desire to reduce future interest obligations, while a decrease suggests stability in existing debt terms.
- How does debt conversion inducement expense compare across companies?
- Common in biotech companies managing convertible notes; peers often show periodic spikes during refinancing cycles.